Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study-Reference-Cited by-同舟云学术

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Published:2016-11-10 Issue:4 Volume:54 Page:288-296
ISSN:0022-2593
Container-title:Journal of Medical Genetics
language:en
Short-container-title:J Med Genet

Author:

Hughes Derralynn A,Nicholls Kathleen,Shankar Suma P,Sunder-Plassmann Gere,Koeller David,Nedd Khan,Vockley Gerard,Hamazaki Takashi,Lachmann Robin,Ohashi Toya,Olivotto Iacopo,Sakai Norio,Deegan Patrick,Dimmock David,Eyskens François,Germain Dominique P,Goker-Alpan Ozlem,Hachulla Eric,Jovanovic Ana,Lourenco Charles M,Narita Ichiei,Thomas Mark,Wilcox William R,Bichet Daniel G,Schiffmann Raphael,Ludington Elizabeth,Viereck Christopher,Kirk John,Yu Julie,Johnson Franklin,Boudes Pol,Benjamin Elfrida R,Lockhart David J,Barlow Carrolee,Skuban Nina,Castelli Jeffrey P,Barth Jay,Feldt-Rasmussen Ulla

Publisher

BMJ

Subject

Genetics (clinical),Genetics

Reference60 articles.

1. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency;Brady;N Engl J Med,1967

2. Fabry disease;Germain;Orphanet J Rare Dis,2010

3. Accelerated transport and maturation of lysosomal a-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor;Fan;Nat Med,1999

4. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease;Khanna;Mol Ther,2010

5. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines;Benjamin;J Inherit Metab Dis,2009

Cited by 287 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabry disease management: Current status, therapeutic challenges, and future horizons in drug delivery and artificial intelligence assisted diagnosis;Journal of Drug Delivery Science and Technology;2024-10

2. CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells;Atherosclerosis;2024-10

3. Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement;International Journal of Molecular Sciences;2024-09-09

4. Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA;Molecular Genetics and Metabolism;2024-09

5. Precise subcellular targeting approaches for organelle-related disorders;Advanced Drug Delivery Reviews;2024-09